Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Trump Says Anthropic No Longer Seen as National Security Threat 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
TUSTIN, Calif., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of previously treated non-small cell lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Contacts: Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 [email protected] Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
